Illumina Inc. (ILMN) Lowered to Hold at Vetr Inc.
Illumina Inc. (NASDAQ:ILMN) was downgraded by stock analysts at Vetr from a “buy” rating to a “hold” rating in a research note issued on Monday. They currently have a $187.86 target price on the life sciences company’s stock. Vetr‘s price objective would indicate a potential upside of 1.63% from the stock’s previous close.
Other research analysts have also issued reports about the stock. Canaccord Genuity set a $165.00 price objective on shares of Illumina and gave the stock a “hold” rating in a report on Friday. Citigroup Inc. increased their price objective on shares of Illumina from $175.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, September 12th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $190.00 price objective on the stock in a report on Friday, August 26th. CL King lowered shares of Illumina from a “buy” rating to a “neutral” rating in a report on Monday, August 22nd. Finally, Argus increased their price objective on shares of Illumina from $175.00 to $185.00 and gave the stock a “buy” rating in a report on Monday, August 8th. One research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $165.56.
Illumina (NASDAQ:ILMN) traded up 0.20% on Monday, reaching $184.85. 1,889,978 shares of the company’s stock traded hands. Illumina has a 52 week low of $127.10 and a 52 week high of $196.47. The firm has a market capitalization of $27.10 billion, a P/E ratio of 63.30 and a beta of 0.47. The stock has a 50-day moving average of $175.01 and a 200 day moving average of $156.56.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/illumina-inc-ilmn-lowered-to-hold-at-vetr-inc.html
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The company had revenue of $600 million for the quarter, compared to analysts’ expectations of $31.91 million. During the same period last year, the company earned $0.80 EPS. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. On average, equities analysts expect that Illumina will post $3.53 EPS for the current fiscal year.
In related news, Director Robert S. Epstein sold 300 shares of Illumina stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $170.27, for a total transaction of $51,081.00. Following the sale, the director now directly owns 7,224 shares in the company, valued at $1,230,030.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $172.99, for a total transaction of $3,459,800.00. Following the sale, the director now owns 508,061 shares in the company, valued at $87,889,472.39. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.
Several large investors have recently modified their holdings of ILMN. Glenmede Trust Co. NA boosted its stake in shares of Illumina by 26.2% in the first quarter. Glenmede Trust Co. NA now owns 3,660 shares of the life sciences company’s stock worth $593,000 after buying an additional 760 shares in the last quarter. Virginia Retirement System bought a new stake in shares of Illumina during the first quarter worth $385,000. IFP Advisors Inc boosted its stake in shares of Illumina by 215.6% in the first quarter. IFP Advisors Inc now owns 1,133 shares of the life sciences company’s stock worth $184,000 after buying an additional 774 shares in the last quarter. Prudential Financial Inc. boosted its stake in shares of Illumina by 0.7% in the first quarter. Prudential Financial Inc. now owns 179,455 shares of the life sciences company’s stock worth $29,092,000 after buying an additional 1,300 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. bought a new stake in shares of Illumina during the first quarter worth $403,000. Institutional investors and hedge funds own 95.22% of the company’s stock.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.